ASH 2018 | LCL161 for primary myelofibrosis: a new therapy in the field

Naveen Pemmaraju

Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX., presents the results from a Phase II study (NCT02098161) of the SMAC mimetic LCL161 in patients with myelofibrosis (MF). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Pemmaraju explains how treatment options are limited beyond JAK inhibitors, thus novel compounds are much needed.

Share this video